Condition (MeSH)
Ventricular Dysfunction, Left
ClinicalTrials.gov lists 314 trials for Ventricular Dysfunction, Left or a narrower condition beneath it. Bayer has the most among industry and government lead sponsors, with 5.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
254 of the 314 trials are tagged with Ventricular Dysfunction, Left itself; the rest are tagged with a narrower condition beneath it.
When did Ventricular Dysfunction, Left trials start? (28)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 21
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 17 |
| 2025 | 17 |
| 2024 | 20 |
| 2023 | 21 |
| 2022 | 15 |
| 2021 | 20 |
| 2020 | 19 |
| 2019 | 18 |
| 2018 | 13 |
| 2017 | 10 |
Showing 10 of 28 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 20 trials starting in 2026 and about 20 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 36 months from start to primary completion across 29 trials still running at the 2026-10-09 snapshot; registered median of 31 months across 176 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Ventricular Dysfunction, Left trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 4 |
| Phase 1/2 | 8 |
| Phase 2 | 22 |
| Phase 2/3 | 4 |
| Phase 3 | 29 |
| Phase 4 | 22 |
| Not applicable | 88 |
| Observational | 137 |
How many Ventricular Dysfunction, Left trials are recruiting? (9)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 18 |
| Recruiting | 49 |
| Enrolling by invitation | 3 |
| Active, not recruiting | 16 |
| Completed | 150 |
Showing 5 of 9 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Ventricular Dysfunction, Left trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Bayer | 5 |
| Eko Devices, Inc. | 4 |
| Medtronic Cardiac Rhythm and Heart Failure | 4 |
| Abbott Medical Devices | 3 |
| Abiomed Inc. | 3 |
Which drugs are being tested for Ventricular Dysfunction, Left? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| VALSARTAN | 6 |
| NEBIVOLOL | 2 |
| BMS-512148 | 2 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Carvedilol CR | 3 |
| Control (placebo) group | 3 |
| Metoprolol XL | 3 |
| Valsartan and Sacubitril | 3 |
| Adult stem cells | 3 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Ventricular Dysfunction, Left trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Cardiac failure | 1,246 | 4 |
| Second secondary endpoint | 947 | 1 |
| Hospitalization for any cause | 900 | 1 |
| Primary end point | 695 | 1 |
| Firt secondary endpoint | 662 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Ventricular Dysfunction, Left? (1,910)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Does CMR improve aetiological sub-phenotyping beyond echocardiography in patients with elevated LV filling pressure? A prospective registry study (PREFER-CMR). | BMJ open | 2026 | Yes |
| Characterization and Mortality Risk of Impaired Left Ventricular Filling in Chronic Obstructive Pulmonary Disease. | American journal of respiratory and critical care medicine | 2025 | Yes |
| Comprehensive CMR evaluation including 4D flow-derived E/A vorticity ratio in overweight adults with and without type 2 diabetes mellitus. | Cardiovascular diabetology | 2025 | Yes |
| Prevalence of frequent premature ventricular contractions and left-ventricular systolic dysfunction in patients receiving Holter monitoring. | Journal of cardiovascular electrophysiology | 2025 | Yes |
| Five-year outcomes with self-expanding versus balloon-expandable TAVI in patients with left ventricular systolic dysfunction. | American heart journal | 2025 | Yes |
Showing 5 of 1,910 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.